Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other financing activities (2020 - 2025)

C4 Therapeutics (CCCC) has 6 years of Other financing activities data on record, last reported at $1000.0 in Q4 2025.

  • For Q4 2025, Other financing activities changed 0.0% year-over-year to $1000.0; the TTM value through Dec 2025 reached $274000.0, down 28.27%, while the annual FY2025 figure was $274000.0, 28.27% down from the prior year.
  • Other financing activities reached $1000.0 in Q4 2025 per CCCC's latest filing, down from $164000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $11.3 million in Q2 2021 and bottomed at -$286000.0 in Q4 2021.
  • Average Other financing activities over 5 years is $786562.5, with a median of $106500.0 recorded in 2023.
  • Peak YoY movement for Other financing activities: soared 7433.33% in 2022, then plummeted 52.73% in 2023.
  • A 5-year view of Other financing activities shows it stood at -$286000.0 in 2021, then soared by 152.45% to $150000.0 in 2022, then plummeted by 100.67% to -$1000.0 in 2023, then soared by 200.0% to $1000.0 in 2024, then changed by 0.0% to $1000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $1000.0 in Q4 2025, $164000.0 in Q3 2025, and $109000.0 in Q1 2025.